Interferon alpha - Swedish Orphan Biovitrim

Drug Profile

Interferon alpha - Swedish Orphan Biovitrim

Alternative Names: HuIFN-alpha-Le; Leu-IFN; Multiferon

Latest Information Update: 24 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Viragen
  • Developer Swedish Orphan Biovitrum; Viragen
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Hairy cell leukaemia; Hepatitis B; Hepatitis C; Malignant melanoma
  • Discontinued Influenza virus infections

Most Recent Events

  • 24 Mar 2015 The product is approved for Malignant melanoma in Europe
  • 30 Oct 2014 Swedish Orphan Biovitrum announces its decision to cease manufacturing of Multiferon® and close its production site in Umeå
  • 14 Jan 2010 Biovitrum has merged with Swedish Orphan to form Swedish Orphan Biovitrum
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top